Allergan pays top dollar for 'stepping stones' from neurology to dermatology
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Needham & Company Reiterates Buy on Dermira (DERM) Following Licensing Agreement
September 21, 2016 7:41 AM EDTNeedham & Company reiterated a Buy rating and $46.00 price target on Dermira (NASDAQ: DERM) following the company's exclusive licensing agreement with Maruho to develop and commercialize DRM04 in Japan. The licensing agreement provides DERM with $25MM in upfront cash, up to $70MM in milestone payments and sales royalties in the low-double... More
Piper Jaffray Downgrades Vitae Pharmaceuticals (VTAE) to Neutral
September 20, 2016 1:37 PM EDTPiper Jaffray downgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Vitae Pharmaceuticals click here. For more ratings news on Vitae Pharmaceuticals click here.
Shares of Vitae Pharmaceuticals closed at $20.85 yesterday.
... More